Unichem Labs has extended the tenure of its MD as CEO for three years, following a board decision. The company reported a revenue of INR 2202 crore and a net profit of INR 253 crore in FY26. Additionally, cost and internal auditors have been reappointed for FY27.

Unichem Labs experiences a significant decrease in Q4 net profit, falling by 79% year-over-year to 110 million INR. Despite a slight decline in quarterly revenue, the company reported earnings of 5.8 billion INR compared to 5.9 billion INR last year.

Despite a significant 79.4% drop in quarterly net profit for Unichem Labs, and a 2.1% decrease in revenue to ₹575 crores, their shares have seen a slight increase of 0.9%, reaching ₹372.50 on the BSE, possibly indicating investor optimism or resilience despite weak results.

Unichem Pharma USA has voluntarily recalled their 5mg Buspirone tablets due to a discrepancy in quality during a 12-month stability test. No reports of adverse events have been received, but the company stresses its commitment to patient safety and product quality.

ICRA maintains a high rating ('A') for Unichem Labs' bank loans worth INR 180 crores, signifying the company's stable credit standing and no changes in its creditworthiness.